Millennium Management Portfolio holdings
Millennium Management, founded in 1989 by Israel (Izzy) Englander and Ronald Shear and headquartered in New York City, is a global multi-strategy hedge fund managing over $71 billion in assets as of late 2024, employing a decentralized model with over 300 independent trading teams. Operating across equities, fixed income, commodities, currencies, and derivatives, the firm uses a mix of quantitative and fundamental strategies, providing its portfolio managers with capital, infrastructure, and autonomy to pursue diverse investment approaches while enforcing strict risk management. With more than 5,400 employees across offices in London, Hong Kong, Singapore, and beyond, Millennium has evolved from its initial $35 million seed capital—partly from the Belzberg family—into a titan of the hedge fund world, known for its ability to attract top talent and deliver consistent returns. Under Englander’s leadership as chairman and CEO, the firm remains a low-profile yet highly influential force in global finance.
Top Buys
| 1 |
SPDR S&P 500 ETF Trust
SPY
|
+$1.43B |
| 2 |
Microsoft
MSFT
|
+$671M |
| 3 |
Spotify
SPOT
|
+$586M |
| 4 |
iShares Bitcoin Trust
IBIT
|
+$456M |
| 5 |
Eli Lilly
LLY
|
+$406M |
Top Sells
| 1 |
Apple
AAPL
|
+$2.7B |
| 2 |
Amazon
AMZN
|
+$1.48B |
| 3 |
Merck
MRK
|
+$884M |
| 4 |
Broadcom
AVGO
|
+$823M |
| 5 |
iShares Core S&P 500 ETF
IVV
|
+$698M |
Sector Composition
| 1 | Technology | 15.81% |
| 2 | Healthcare | 13.31% |
| 3 | Financials | 13.08% |
| 4 | Industrials | 11.5% |
| 5 | Consumer Discretionary | 8.86% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
2801
Kelly Services Class A
KELYA
$481M
| $997K | ﹤0.01% |
46,568
-16,300
| -26% | -$349K |
|
2802
Astrana Health
ASTH
$1.38B
| $993K | ﹤0.01% |
17,133
-37,249
| -68% | -$2.16M |
|
2803
Ramaco Resources Class A
METC
$1.6B
| $992K | ﹤0.01% |
87,606
-362,013
| -81% | -$4.1M |
|
2804
Ultralife
ULBI
$114M
| $990K | ﹤0.01% |
109,481
+24,308
| +29% | +$220K |
|
2805
Nuveen Preferred & Income Opportunities Fund
JPC
$2.66B
| $988K | ﹤0.01% |
122,436
+84,722
| +225% | +$684K |
|
|
FSCO
2806
FS Credit Opportunities Corp
FSCO
$1.48B
| $986K | ﹤0.01% |
+155,336
| New | +$986K |
|
2807
Black Diamond Therapeutics
BDTX
$185M
| $986K | ﹤0.01% |
226,745
-778,133
| -77% | -$3.38M |
|
2808
Cato Corp
CATO
$91.1M
| $986K | ﹤0.01% |
197,591
-165,921
| -46% | -$828K |
|
2809
Korea Electric Power
KEP
$17.2B
| $984K | ﹤0.01% |
126,851
+40,496
| +47% | +$314K |
|
2810
Hamilton Lane
HLNE
$6.53B
| $984K | ﹤0.01% |
5,844
-633,132
| -99% | -$107M |
|
2811
Diodes
DIOD
$2.44B
| $980K | ﹤0.01% |
15,293
-17,516
| -53% | -$1.12M |
|
2812
Lyell Immunopharma
LYEL
$246M
| $980K | ﹤0.01% |
35,503
-4,975
| -12% | -$137K |
|
2813
Root
ROOT
$1.53B
| $979K | ﹤0.01% |
+25,910
| New | +$979K |
|
2814
The RMR Group
RMR
$288M
| $977K | ﹤0.01% |
38,492
-10,924
| -22% | -$277K |
|
2815
Anika Therapeutics
ANIK
$125M
| $976K | ﹤0.01% |
39,509
+8,797
| +29% | +$217K |
|
2816
Daily Journal
DJCO
$562M
| $973K | ﹤0.01% |
+1,986
| New | +$973K |
|
2817
Starwood Property Trust
STWD
$7.52B
| $972K | ﹤0.01% |
47,685
+3,608
| +8% | +$73.5K |
|
2818
Imperial Oil
IMO
$46.3B
| $969K | ﹤0.01% |
13,753
+7,180
| +109% | +$506K |
|
2819
Seres Therapeutics
MCRB
$139M
| $967K | ﹤0.01% |
51,098
-37,782
| -43% | -$715K |
|
2820
Arbutus Biopharma
ABUS
$855M
| $966K | ﹤0.01% |
250,960
+41,991
| +20% | +$162K |
|
2821
Boston Omaha
BOC
$425M
| $965K | ﹤0.01% |
+64,870
| New | +$965K |
|
|
BGB
2822
Blackstone Strategic Credit 2027 Term Fund
BGB
$559M
| $964K | ﹤0.01% |
78,280
+58,669
| +299% | +$723K |
|
|
ME
2823
DELISTED
23andMe Holding Co. Class A Common Stock
ME
| $954K | ﹤0.01% |
137,319
-109,927
| -44% | -$764K |
|
2824
BridgeBio Pharma
BBIO
$9.79B
| $954K | ﹤0.01% |
37,472
-204,308
| -85% | -$5.2M |
|
2825
Zegna
ZGN
$2.22B
| $954K | ﹤0.01% |
+96,951
| New | +$954K |
|